Newbridge Financial Services Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-12,500
Closed -$659 – 1503
2022
Q4
$659 Hold
12,500
– – ﹤0.01% 1344
2022
Q3
$15K Sell
12,500
-653
-5% -$1.02K 0.01% 789
2022
Q2
$24K Buy
13,153
+6,500
+98% +$9.59K 0.01% 612
2022
Q1
$13K Hold
6,653
– – 0.01% 873
2021
Q4
$18K Hold
6,653
– – 0.01% 769
2021
Q3
$30K Buy
6,653
+3,500
+111% +$16.9K 0.02% 558
2021
Q2
$18K Hold
3,153
– – 0.01% 815
2021
Q1
$22K Buy
3,153
+1,653
+110% +$11.1K 0.02% 674
2020
Q4
$7K Hold
1,500
– – 0.01% 804
2020
Q3
$9K Buy
+1,500
New +$8.97K 0.01% 711

Other funds holding CLVS

Newbridge Financial Services Group's CLVS Position: Q1 2023 in Review

Newbridge Financial Services Group sold out of Clovis Oncology, Inc. (CLVS) in Q1 2023, closing a stake of 12,500 shares — an estimated $659 sold.

Newbridge Financial Services Group first reported a position in CLVS in Q3 2020 and held it in 10 quarters. The position peaked at $30K in Q3 2021. 2 funds tracked by Wall St. Rank hold CLVS as of Q1 2023.

  • Newbridge Financial Services Group reported no remaining Clovis Oncology, Inc. position as of Q1 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 12,500 Clovis Oncology, Inc. shares in Q1 2023, an estimated $659.
  • Newbridge Financial Services Group first reported a position in Clovis Oncology, Inc. in Q3 2020 and held it in 10 quarters.
  • Newbridge Financial Services Group's Clovis Oncology, Inc. position peaked at $30K in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2023.

Based on Newbridge Financial Services Group's 13F filing for Q1 2023, filed 18 Apr 2023.